<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xml:lang="EN" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?origin publisher?><?properties no_embargo?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Mol Med</journal-id><journal-title>Journal of Molecular Medicine (Berlin, Germany)</journal-title><issn pub-type="ppub">0946-2716</issn><issn pub-type="epub">1432-1440</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">490</article-id><article-id pub-id-type="doi">10.1007/s00109-009-0490-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title><italic>OSBPL10</italic>, a novel candidate gene for high triglyceride trait in dyslipidemic Finnish subjects, regulates cellular lipid metabolism</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Perttil&#x000e4;</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Merikanto</surname><given-names>Krista</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Naukkarinen</surname><given-names>Jussi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Surakka</surname><given-names>Ida</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martin</surname><given-names>Nicolas W.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tanhuanp&#x000e4;&#x000e4;</surname><given-names>Kimmo</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Grimard</surname><given-names>Vinciane</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Taskinen</surname><given-names>Marja-Riitta</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thiele</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Salomaa</surname><given-names>Veikko</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jula</surname><given-names>Antti</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Perola</surname><given-names>Markus</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Virtanen</surname><given-names>Ismo</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Peltonen</surname><given-names>Leena</given-names></name><address><phone>+44-1223-496845</phone><fax>+44-1223-496820</fax><email>leena.peltonen@sanger.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Olkkonen</surname><given-names>Vesa M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>National Institute for Health and Welfare/Public Health Genomics Unit, Biomedicum, P.O. Box 104, 00251 Helsinki, Finland </aff><aff id="Aff2"><label>2</label>FIMM, Institute for Molecular Medicine Finland, University of Helsinki, P.O. Box 20, 00014 Helsinki, Finland </aff><aff id="Aff3"><label>3</label>Institute of Biomedicine/Anatomy, University of Helsinki, P.O. Box 63, 00014 Helsinki, Finland </aff><aff id="Aff4"><label>4</label>Queensland Institute of Medical Research, 300 Herston Road, Brisbane, 4029 Australia </aff><aff id="Aff5"><label>5</label>Light microscopy Unit, Institute of Biotechnology, University of Helsinki, 00014 Helsinki, Finland </aff><aff id="Aff6"><label>6</label>Max-Planck-Institute of Molecular Cell Biology and Genetics, Pfotenhauerstrasse 108, 01307 Dresden, Germany </aff><aff id="Aff7"><label>7</label>Department of Medicine, Division of Cardiology, Helsinki University Hospital and Biomedicum, Haartmaninkatu 8, 00290 Helsinki, Finland </aff><aff id="Aff8"><label>8</label>Department of Chronic Disease Prevention, National Institute for Health and Welfare, P.O. Box 30, 00271 Helsinki, Finland </aff><aff id="Aff9"><label>9</label>National Institute for Health and Welfare, 20720 Turku, Finland </aff><aff id="Aff10"><label>10</label>Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA UK </aff><aff id="Aff11"><label>11</label>Department of Medical Genetics, University of Helsinki, 00014 Helsinki, Finland </aff><aff id="Aff12"><label>12</label>The Broad Institute, Boston, MA 02142 USA </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>6</month><year>2009</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2009</year></pub-date><volume>87</volume><issue>8</issue><fpage>825</fpage><lpage>835</lpage><history><date date-type="received"><day>6</day><month>4</month><year>2009</year></date><date date-type="rev-recd"><day>14</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>25</day><month>5</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2009</copyright-statement></permissions><abstract xml:lang="EN"><p>Analysis of variants in three genes encoding oxysterol-binding protein (OSBP) homologues (<italic>OSBPL2</italic>, <italic>OSBPL9</italic>, <italic>OSBPL10</italic>) in Finnish families with familial low high-density lipoprotein (HDL) levels (<italic>N</italic>&#x02009;=&#x02009;426) or familial combined hyperlipidemia (<italic>N</italic>&#x02009;=&#x02009;684) revealed suggestive linkage of <italic>OSBPL10</italic> single-nucleotide polymorphisms (SNPs) with extreme end high triglyceride (TG; &#x0003e;90th percentile) trait. Prompted by this initial finding, we carried out association analysis in a metabolic syndrome subcohort (Genmets) of Health2000 examination survey (<italic>N</italic>&#x02009;=&#x02009;2,138), revealing association of multiple <italic>OSBPL10</italic> SNPs with high serum TG levels (&#x0003e;95th percentile). To investigate whether <italic>OSBPL10</italic> could be the gene underlying the observed linkage and association, we carried out functional experiments in the human hepatoma cell line Huh7. Silencing of <italic>OSBPL10</italic> increased the incorporation of [<sup>3</sup>H]acetate into cholesterol and both [<sup>3</sup>H]acetate and [<sup>3</sup>H]oleate into triglycerides and enhanced the accumulation of secreted apolipoprotein B100 in growth medium, suggesting that the encoded protein ORP10 suppresses hepatic lipogenesis and very-low-density lipoprotein production. ORP10 was shown to associate dynamically with microtubules, consistent with its involvement in intracellular transport or organelle positioning. The data introduces <italic>OSBPL10</italic> as a gene whose variation may contribute to high triglyceride levels in dyslipidemic Finnish subjects and provides evidence for ORP10 as a regulator of cellular lipid metabolism.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s00109-009-0490-z) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Cholesterol</kwd><kwd>High-density lipoprotein</kwd><kwd>Microtubule</kwd><kwd>Oxysterol-binding protein</kwd><kwd>Single-nucleotide polymorphism</kwd><kwd>Triglyceride</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2009</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Families of proteins with homology to the carboxy-terminal ligand binding domain of oxysterol binding protein (OSBP) are suggested to function in various cellular processes such as lipid metabolism, intracellular lipid transport, membrane trafficking, and cell signaling [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. In humans, the gene family consists of 12 members, which are denoted OSBP-like genes (<italic>OSBPL</italic>), while the encoded proteins are called either OSBP-like (OSBPL) or OSBP-related proteins (ORP) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><p>OSBP is the most extensively studied member of the mammalian ORP protein family. OSBP acts as a sterol sensor that integrates the cellular sterol status with sphingomyelin metabolism [<xref ref-type="bibr" rid="CR5">5</xref>] and controls the dephosphorylation and hence the activity of extracellular signal-regulated kinases, ERK [<xref ref-type="bibr" rid="CR6">6</xref>]. We recently showed that OSBP overexpression in mouse liver impacts serum very-low-density lipoprotein triglyceride (TG) levels and hepatic TG synthesis through up-regulation of the expression and activity of sterol regulatory element binding protein 1c (SREBP-1c) [<xref ref-type="bibr" rid="CR7">7</xref>], a major insulin-responsive regulator of hepatic and adipose tissue lipogenesis. Over-expression of human ORP1L in mouse macrophages resulted in impaired cholesterol efflux and increased size of atherosclerotic lesions in low-density lipoprotein (LDL)-receptor deficient mice [<xref ref-type="bibr" rid="CR8">8</xref>]. Furthermore, our latest data demonstrates a role of the OSBP homologue ORP8 as factor that suppresses, most likely via an indirect mechanism, the expression of ATP-binding cassette transporter A1 (ABCA1) [<xref ref-type="bibr" rid="CR9">9</xref>], a key mediator of high-density lipoprotein (HDL) biogenesis. Moreover, ORP2, ORP4S, and ORP9 have been implicated in cellular sterol or neutral lipid metabolism [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>], lending further support to the view that ORP family members play important roles in cellular lipid metabolism.</p><p>In the present study, we assessed whether allelic diversity of the <italic>OSBPL2</italic>, <italic>OSBPL9</italic>, or <italic>OSBPL10</italic> genes contributes to extreme serum lipid levels in Finnish families ascertained for low HDL-cholesterol or familial combined hyperlipidemia (FCHL, common dyslipidemias associated with increased risk of premature coronary heart disease [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. Variants of <italic>OSBPL10</italic> displayed suggestive linkage with high triglyceride levels in the families, and association analysis in a metabolic syndrome study sample (<italic>N</italic>&#x02009;=&#x02009;2,138) strengthened the notion that variation in <italic>OSBPL10</italic> may influence serum TG levels in Finnish dyslipidemic subjects. RNA interference experiments in cultured human hepatoma cells suggested that the encoded protein, ORP10, acts as a regulator of cellular lipid biosyntheses and apolipoprotein B-100 (apoB100) secretion, lending functional support to the genetic findings.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Dyslipidemic cohorts and genotyping strategy</title><p>The FCHL families (53 families, 684 subjects) were recruited through the Helsinki, Turku, and Kuopio University Central Hospitals and the inclusion/exclusion criteria for the probands have been described [<xref ref-type="bibr" rid="CR17">17</xref>]. The low-HDL families (39 families, 426 subjects) were collected in the Helsinki and Turku University Hospitals, and probands were required to have HDL-cholesterol (HDL-C) levels &#x0003c;10th age- and sex-specific percentile of the Finnish population and angiographically verified coronary heart disease and are more fully described in [<xref ref-type="bibr" rid="CR18">18</xref>]. Phenotypic information on the study subjects and the distributions of their serum HDL-C and TG concentrations are displayed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and in Electronic Supplementary Materials Fig.&#x000a0;<xref ref-type="supplementary-material" rid="MOESM3">1</xref>, respectively. DNA extraction, single-nucleotide polymorphism (SNP) genotyping, and data analysis were carried out as described in <xref ref-type="supplementary-material" rid="MOESM4">Electronic Supplementary Materials method descriptions</xref>. Detailed information on the SNPs analyzed is displayed in Electronic Supplementary Materials Table&#x000a0;<xref ref-type="supplementary-material" rid="MOESM2">1</xref> and in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. <table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Phenotypic characteristics of the low-HDL and FCHL study samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Trait</th><th>Males</th><th>Females</th><th>Total</th></tr></thead><tbody><tr><td rowspan="6">Low-HDL</td><td><italic>N</italic></td><td>327</td><td>338</td><td>665</td></tr><tr><td>Age<sup>a</sup> (years)</td><td>45.30&#x02009;&#x000b1;&#x02009;22.08</td><td>45.61&#x02009;&#x000b1;&#x02009;20.5</td><td>45.47&#x02009;&#x000b1;&#x02009;21.2</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>25.47&#x02009;&#x000b1;&#x02009;4.25</td><td>24.76&#x02009;&#x000b1;&#x02009;4.66</td><td>25.09&#x02009;&#x000b1;&#x02009;4.5</td></tr><tr><td>TC (mmol/l)</td><td>5,40&#x02009;&#x000b1;&#x02009;1.16</td><td>5,47&#x02009;&#x000b1;&#x02009;1.07</td><td>5,44&#x02009;&#x000b1;&#x02009;1.11</td></tr><tr><td>HDL (mmol/l)</td><td>1.02&#x02009;&#x000b1;&#x02009;0.3</td><td>1.35&#x02009;&#x000b1;&#x02009;0.38</td><td>1.20&#x02009;&#x000b1;&#x02009;0.38</td></tr><tr><td>TG (mmol/l)</td><td>1.59&#x02009;&#x000b1;&#x02009;0.8</td><td>1.45&#x02009;&#x000b1;&#x02009;0.79</td><td>1.51&#x02009;&#x000b1;&#x02009;0.8</td></tr><tr><td rowspan="6">FCHL</td><td><italic>N</italic></td><td>687</td><td>632</td><td>1,319</td></tr><tr><td>Age (years)</td><td>37.60&#x02009;&#x000b1;&#x02009;20.44</td><td>37.91&#x02009;&#x000b1;&#x02009;20.35</td><td>37.7&#x02009;&#x000b1;&#x02009;20.4</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>25.56&#x02009;&#x000b1;&#x02009;4.46</td><td>24.90&#x02009;&#x000b1;&#x02009;5.29</td><td>25.22&#x02009;&#x000b1;&#x02009;5.02</td></tr><tr><td>TC (mmol/l)</td><td>5.84&#x02009;&#x000b1;&#x02009;1.43</td><td>5.85&#x02009;&#x000b1;&#x02009;1.32</td><td>5.84&#x02009;&#x000b1;&#x02009;1.37</td></tr><tr><td>HDL (mmol/l)</td><td>1.15&#x02009;&#x000b1;&#x02009;0.36</td><td>1.39&#x02009;&#x000b1;&#x02009;0.41</td><td>1.27&#x02009;&#x000b1;&#x02009;0.41</td></tr><tr><td>TG (mmol/l)</td><td>2.11&#x02009;&#x000b1;&#x02009;1.88</td><td>1.59&#x02009;&#x000b1;&#x02009;1.27</td><td>1.85&#x02009;&#x000b1;&#x02009;1.6</td></tr></tbody></table><table-wrap-foot><p>The data represent mean &#x000b1; SD</p><p><italic>BMI</italic> body mass index, <italic>TC</italic> total cholesterol, <italic>HDL</italic> high-density lipoprotein cholesterol, <italic>TG</italic> triglycerides</p><p><sup>a</sup>Subjects under the age of 20&#x000a0;years were excluded</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Location and linkage disequilibrium (LD) relationships of the investigated SNPs in <italic>OSBPL10</italic>. Exons 1&#x02013;13 as well as introns 2 and 5 are indicated. The SNPs analyzed in the low-HDL and FCHL family materials are shown <italic>below the gene structure</italic>; those with the highest LOD scores (&#x0003e;2.0) for linkage with high-TG trait are indicated in <italic>red</italic>. The LD relationships between the SNPs are depicted at the <italic>bottom</italic>; Numbers represent <italic>r</italic><sup>2</sup>, the <italic>top</italic> one for FCHL and the <italic>bottom</italic> one for low-HDL families. The SNPs showing strongest association (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) with high TG in the Genmets data set are displayed (<italic>in red</italic>) <italic>above the gene structure</italic></p></caption><graphic position="anchor" xlink:href="109_2009_490_Fig1_HTML" id="MO1"/></fig></p><p>The Genmets sample is subset of 2,212 individuals of the Health2000 study (<ext-link ext-link-type="uri" xlink:href="http://www.terveys2000.fi/doc/methodologyrep.pdf">http://www.terveys2000.fi/doc/methodologyrep.pdf</ext-link>) collected as metabolic syndrome cases and their matched controls. A total of 2,173 of these individuals have been genotyped on Illumina 610K arrays. In this study, 102 SNPs located in <italic>OSBPL10</italic> or its flanking regions were analyzed. For the association analysis, individuals with the TG levels above the 95th population, sex, and age-specific percentile (&#x0003e;3.4&#x000a0;mmol/l) were coded as cases and the rest as controls. The same coding was done for the individuals with the high-density lipoprotein cholesterol values below the 5th percentile (&#x0003c;0.8&#x000a0;mmol/l). For these two dichotomous phenotypes, logistic regression was applied with age and sex as covariates (for details, see <xref ref-type="supplementary-material" rid="MOESM4">Electronic Supplementary Materials method descriptions</xref>).</p><p>The study materials were collected according to the Helsinki declaration, and the ethics committees of the participating centers approved the study design.</p></sec><sec id="Sec4"><title>Generation of a rabbit antibody against ORP10</title><p>A cDNA fragment encoding amino acid residues 1&#x02013;80 of the full-length ORP10 protein (NM_017784) was inserted in pGEX1&#x003bb;T (GE Healthcare, Uppsala, Sweden) for production of a glutathione-<italic>S</italic>-transferase fusion protein in <italic>Escherichia coli</italic> BL21. The protein was purified on Glutathione-Sepharose 4B (GE Healthcare) and used for subcutaneous immunization of New Zealand white rabbits by a standard procedure.</p></sec><sec id="Sec5"><title>Cell culture</title><p>The human hepatoma cell line Huh7 was cultured in Eagle&#x02019;s minimal essential medium with Earle&#x02019;s salts (EMEM, Sigma-Aldrich, St. Louis, MO, USA), 20&#x000a0;mM Hepes, pH&#x02009;7.4, 10% fetal bovine serum (FBS; Gibco/Invitrogen, Grand Island, NY, USA), 100&#x000a0;U/ml penicillin, and 100&#x02009;&#x003bc;g/ml streptomycin. The pancreatic adenocarcinoma cell line PANC-1 was cultured in RPMI 1640 (BioWhittaker, Walkersville, MD, USA), 10% FBS, and the above antibiotics. Caco-2 cells were cultured in EMEM supplemented with 10% FBS, non-essential amino acids, and the above antibiotics.</p></sec><sec id="Sec6"><title>RNA interference</title><p>Huh7 cells were transfected with ORP10-specific (siORP10.1, sense strand CCACAGCCUCAAUCUUGUAdTdT; siORP10.2, GAGAAUUUCCUGUGGAU-UAdTdT) or nontargeting control siRNA (siNT, sense strand UAGCGACUAAACACAUCAAdTdT) using INTERFERin (Polyplus, Illkirch, France) or HiPerFect (Qiagen, Valencia, CA, USA) according to the manufacturers&#x02019; instructions. After 48&#x000a0;h transfection, the cells were either subjected to total RNA isolation by using the RNeasy Mini kit (Qiagen) or used for analysis of cholesterol and triglyceride biosynthesis.</p></sec><sec id="Sec7"><title>Analysis of cholesterol and triglyceride biosynthesis</title><p>Huh7 cells treated with ORP10-specific or nontargeting control siRNAs were labeled with [<sup>3</sup>H]acetic acid or [<sup>3</sup>H]oleic acid, and incorporation of the radioactive tracers into cholesterol or TG was carried out, as specified in <xref ref-type="supplementary-material" rid="MOESM4">Electronic Supplementary Materials method descriptions</xref>.</p></sec><sec id="Sec8"><title>Assays for apoA-I and apoB100 secretion by Huh7 cells</title><p>Huh7 cells treated for 48&#x000a0;h with nontargeting or ORP10-specific siRNAs as specified above were washed with phosphate-buffered saline and transferred into serum-free culture medium. The medium and the cells were harvested at 6, 12, and 24&#x000a0;h. The apoA-I [<xref ref-type="bibr" rid="CR19">19</xref>] and apoB100 (Mabtech, Nacka Strand, Sweden) concentrations in the medium were determined with specific sandwich enzyme-linked immunosorbent assay (ELISA) assays and normalized for total cell protein.</p></sec><sec id="Sec9"><title>mRNA quantification</title><p>Total RNA was isolated from Huh7 cells treated with ORP10 or control siRNAs, and quantitative real-time polymerase chain reaction (PCR) analysis of specific mRNAs was carried out using SYBR-green (Applied Biosystems) as described in <xref ref-type="supplementary-material" rid="MOESM4">Electronic Supplementary Materials method descriptions</xref>. The primers used are specified in Electronic Supplementary Materials Table&#x000a0;<xref ref-type="supplementary-material" rid="MOESM2">2</xref>.</p></sec><sec id="Sec10"><title>Assay for 3-hydroxy-3-methylglutaryl coenzyme A reductase activity</title><p>Huh7 cells treated with ORP10-specific or control siRNAs as specified above were harvested, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity in total membranes of the cells was assayed as detailed in <xref ref-type="supplementary-material" rid="MOESM4">Electronic Supplementary Materials method descriptions</xref>.</p></sec><sec id="Sec11"><title>Analysis of the subcellular localization of ORP10</title><p>The human ORP10 open reading frame (NM_017784) was subcloned into the pEGFP-C (BD Biosciences Clontech, Palo Alto, CA, USA) or pcDNA4HisMax (Invitrogen) vectors for mammalian cell expression. Huh7, PANC-1, or Caco-2 cells cultured in normal serum-containing growth medium were transfected for 24&#x000a0;h using Lipofectamine 2000 (Invitrogen), fixed with paraformaldehyde and processed for immunofluorescence microscopy essentially as described previously [<xref ref-type="bibr" rid="CR20">20</xref>]. The immunofluorescence double stainings carried out, and pretreatments of the cells are described in <xref ref-type="supplementary-material" rid="MOESM4">Electronic Supplementary Materials method descriptions</xref>. Fluorescence recovery after photobleaching (FRAP) in Huh7 cells transfected with EGFP-ORP10 was carried out as detailed in <xref ref-type="supplementary-material" rid="MOESM4">Electronic Supplementary Materials method descriptions</xref>.</p></sec></sec><sec id="Sec12" sec-type="results"><title>Results</title><sec id="Sec13"><title>Single-nucleotide polymorphisms in <italic>OSBPL10</italic> show suggestive linkage with serum triglyceride levels</title><p>We used carefully phenotyped Finnish families ascertained for low HDL or FCHL to investigate the contribution of variation in <italic>OSBPL</italic> genes to extreme ends of lipid traits. Phenotypic information on the study subjects is summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, and the distributions of HDL and TG measurements used as traits in the genetic analyses are depicted in Electronic Supplementary Materials Fig.&#x000a0;<xref ref-type="supplementary-material" rid="MOESM3">1</xref>. Genotyping of tag SNPs of <italic>OSBPL2</italic>, -<italic>9</italic>, and -<italic>10</italic> in 39 families (<italic>N</italic>&#x02009;=&#x02009;426 genotyped individuals) with low-HDL and 53 Finnish FCHL families (<italic>N</italic>&#x02009;=&#x02009;684 genotyped individuals) revealed indications of linkage between multiple SNPs in <italic>OSBPL10</italic> and the status for high TG, which was treated as an affection status and defined as exceeding the population sex- and age-specific 90th percentile (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The indications of linkage emerged mostly in the FCHL families. No evidence for linkage or association could be observed for SNPs of <italic>OSBPL2</italic> and -<italic>9</italic>, so they were excluded from further studies (data not shown). Combining the study materials (92 pedigrees, <italic>N</italic>&#x02009;=&#x02009;1,110 individuals) increased the linkage logarithm of the odds (LOD) scores for a number of SNP variants with the high-TG trait (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The strongest evidence for linkage with the high TG trait was observed for SNP variants rs9853939 (LOD 2.40) and rs9847800 (LOD 2.07), located in intron 2 of <italic>OSBPL10</italic> (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). <table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Linkage and association results for the dichotomized HDL-cholesterol and TG traits in the low-HDL and FCHL families</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Low-HDL</th><th colspan="2">FCHL</th><th colspan="2">Combined</th></tr></thead><tbody><tr><td>SNP <italic>(OSBPL10)</italic></td><td>&#x0003c;10th %<sup>a</sup> HDL</td><td>&#x0003e;90th % TG</td><td>&#x0003c;10th % HDL</td><td>&#x0003e;90th % TG</td><td>&#x0003c;10th % HDL</td><td>&#x0003e;90th % TG</td></tr><tr><td>rs9878129</td><td>0.02 (1)<sup>b</sup></td><td>0.00 (0.07)</td><td>0.25 (1)</td><td><bold>0.78</bold><sup>c</sup>(0.53)</td><td>0.26 (0.24)</td><td><bold>0.71</bold> (0.77)</td></tr><tr><td>rs9847800</td><td>0.43 (0.22)</td><td>0.15 (0.53)</td><td>0.06 (0.54)</td><td><bold>1.36</bold> (0.23)</td><td><bold>0.80</bold> (0.21)</td><td><bold>2.07</bold> (0.50)</td></tr><tr><td>rs9853939</td><td>0.66 (0.19)</td><td>0.00 (0.89)</td><td>0.09 (0.49)</td><td><bold>1.79</bold> (0.82)</td><td><bold>0.98</bold> (0.21)</td><td><bold>2.40</bold> (1)</td></tr><tr><td>rs7644177</td><td>0.01 (0.42)</td><td>0.18 (<bold>0.0005</bold>)</td><td>0.01 (0.74)</td><td>0.12 (0.64)</td><td>0.23 (0.84)</td><td>0.16 (<bold>0.03</bold>)</td></tr><tr><td>rs6807471</td><td>0.40 (0.92)</td><td>0.00 (0.69)</td><td>0.54 (0.26)</td><td>0.01 (0.14)</td><td>0.34 (0.44)</td><td>0.00 (0.39)</td></tr><tr><td>rs9880436</td><td>0.00 (0.67)</td><td>0.36 (0.60)</td><td>0.59 (0.07)</td><td>0.50 (<bold>0.03</bold>)</td><td>0.46 (0.33)</td><td><bold>0.80</bold> (0.14)</td></tr><tr><td>rs11709187</td><td>0.16 (0.17)</td><td>0.00 (0.56)</td><td>0.08 (0.84)</td><td>0.28 (<bold>0.03</bold>)</td><td>0.23 (0.32)</td><td>0.22 (0.08)</td></tr><tr><td>rs2219250</td><td>0.55 (1)</td><td>0.08 (0.75)</td><td><bold>0.74</bold> (0.79)</td><td>0.20 (0.88)</td><td><bold>0.94</bold> (0.84)</td><td>0.41 (1)</td></tr><tr><td>rs2045298</td><td>0.04 (0.14)</td><td>0.00 (0.55)</td><td>0.04 (0.79)</td><td>0.51 (<bold>0.03</bold>)</td><td>0.09 (0.47)</td><td>0.38 (0.07)</td></tr><tr><td>rs2290531</td><td>0.13 (0.6)</td><td>0.02 (0.63)</td><td>0.00 (0.69)</td><td>0.65 (0.84)</td><td>0.00 (0.75)</td><td><bold>1.22</bold> (0.92)</td></tr><tr><td>rs6803685</td><td>0.49 (0.32)</td><td><bold>0.77</bold> (<bold>0.04</bold>)</td><td>0.03 (0.34)</td><td>0.01 (0.72)</td><td>0.52 (0.20)</td><td>0.10 (0.25)</td></tr><tr><td>rs1869849</td><td><bold>0.72</bold> (1)</td><td>0.35 (0.29)</td><td>0.04 (0.76)</td><td>0.10 (0.11)</td><td>0.52 (0.77)</td><td>0.12 (0.75)</td></tr><tr><td>rs2013777</td><td>0.65 (0.53)</td><td>0.00 (0.92)</td><td>0.01 (0.09)</td><td>0.01 (0.48)</td><td>0.03 (0.21)</td><td>0.05 (0.37)</td></tr><tr><td>rs3749405</td><td><bold>0.91</bold> (0.54)</td><td>0.00 (0.92)</td><td>0.01 (0.14)</td><td>0.01 (0.37)</td><td>0.00 (0.19)</td><td>0.004 (0.36)</td></tr><tr><td>rs11058</td><td>0.00 (0.14)</td><td>0.00 (0.58)</td><td>0.00 (0.78)</td><td>0.45 (0.15)</td><td>0.00 (0.57)</td><td>0.12 (0.13)</td></tr><tr><td><bold><italic>N</italic></bold><bold>Affected</bold></td><td>167</td><td>46</td><td>255</td><td>205</td><td>422</td><td>251</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>The percentiles used to diagnose represent age- and sex-specific population cut-off values</p><p><sup>b</sup>The first value represents the LOD score, the number in parentheses represents <italic>p</italic> value for association, given linkage</p><p><sup>c</sup>LOD scores &#x0003e;0.7 and <italic>p</italic> values &#x0003c;0.05 are indicated in bold</p></table-wrap-foot></table-wrap></p><p>We next studied whether the SNP alleles with the best evidence for linkage with the extreme end of TG concentration show correlation with the <italic>OSBPL10</italic> mRNA expression level in fat biopsies withdrawn from 47 individuals belonging to the low-HDL and FCHL families, using transcriptome data acquired with Affymetrix U133 Plus 2.0 microarrays. No significant correlation was detected (data not shown), suggesting that rather than affecting the <italic>OSBPL10</italic> mRNA levels, the SNPs may be in linkage disequilibrium (LD) with a yet unidentified functional variant.</p><p>Prompted by the suggestive linkage observation, we moved on to analyze the extreme ends of the HDL and TG distribution in a subcohort (Genmets) of the Health2000 population cohort, consisting of subjects with metabolic syndrome and matched healthy controls. Similar to the analysis done in the family sample, in this data set (<italic>N</italic>&#x02009;=&#x02009;2,138) individuals with the TG above the 95th percentile were coded as cases and the rest as controls. A corresponding dichotomous division was made using HDL cholesterol &#x0003c;5th percentile as the cut-off. The analysis revealed association of multiple SNPs (21 SNPs with <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, nine SNPs with <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) in <italic>OSBPL10</italic> or its flanking regions with high TG levels (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Also, a tendency of association with low HDL was observed, but this failed to reach statistical significance after multiple testing correction (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>). The SNPs showing strongest association with high TG in the Genmets data set were, with the exception of one, located in <italic>OSBPL10</italic> intron 5 and contained within a single LD block (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). <fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Association of <italic>OSBPL10</italic> SNPs with high TG (&#x0003e;95th percentile) of low HDL (&#x0003c;5th percentile) in the Genmets study material. Expected and observed <italic>p</italic> values are depicted. The <italic>axes</italic> represent &#x02212;log10 of the <italic>p</italic> values, the <italic>straight line</italic> indicating the expected <italic>p</italic> values assuming no association</p></caption><graphic position="anchor" xlink:href="109_2009_490_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Genmets study material: <italic>OSBPL10</italic> SNPs associated with high TG (&#x0003e;95th percentile), <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01</p></caption><table frame="hsides" rules="groups"><thead><tr><th>SNP</th><th>Position, bp</th><th>Effect allele</th><th>Effect all. frequency</th><th>Odds ratio</th><th>P-value</th></tr></thead><tbody><tr><td>rs11716163</td><td>31782580</td><td>T</td><td char="." align="char">0.2633</td><td char="." align="char">1.771</td><td char="." align="char">0.000179</td></tr><tr><td>rs7653447</td><td>31814139</td><td>A</td><td char="." align="char">0.3383</td><td char="." align="char">0.5882</td><td char="." align="char">0.001484</td></tr><tr><td>rs2168422</td><td>31779846</td><td>T</td><td char="." align="char">0.2921</td><td char="." align="char">0.5827</td><td char="." align="char">0.002511</td></tr><tr><td>rs9851048</td><td>31806124</td><td>T</td><td char="." align="char">0.3324</td><td char="." align="char">0.6091</td><td char="." align="char">0.003025</td></tr><tr><td>rs7643025</td><td>31814246</td><td>A</td><td char="." align="char">0.2527</td><td char="." align="char">0.5911</td><td char="." align="char">0.004931</td></tr><tr><td>rs12171283</td><td>31797341</td><td>G</td><td char="." align="char">0.2659</td><td char="." align="char">0.6077</td><td char="." align="char">0.00621</td></tr><tr><td>rs9310978</td><td>31801771</td><td>T</td><td char="." align="char">0.2656</td><td char="." align="char">0.6085</td><td char="." align="char">0.006334</td></tr><tr><td>rs3792551</td><td>31681904</td><td>T</td><td char="." align="char">0.09962</td><td char="." align="char">0.4152</td><td char="." align="char">0.007563</td></tr><tr><td>rs12632849</td><td>31767922</td><td>T</td><td char="." align="char">0.3582</td><td char="." align="char">1.464</td><td char="." align="char">0.00786</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec14"><title>ORP10 modulates hepatocellular lipogenesis</title><p>We employed siRNA-mediated silencing of ORP10 expression in a human hepatoma cell line Huh7 to investigate the role of ORP10 in hepatocellular lipid biosyntheses. Transfection of the two independent siRNAs used, siORP10.1 and siORP10.2, resulted in approximately 90% reduction of the endogenous Huh7 cell ORP10 protein (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). To assess the role of ORP10 in hepatocellular cholesterol biosynthesis, we determined the incorporation of [<sup>3</sup>H]acetic acid into cholesterol in cells transfected with scrambled control or ORP10-specific siRNAs. Silencing of ORP10 resulted in a significant, 40&#x02013;50% increase of [<sup>3</sup>H]free cholesterol and a mild elevation of [<sup>3</sup>H]cholesterol esters, suggesting enhancement of cholesterol biosynthetic activity (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>). We also quantified from the same experiments the [<sup>3</sup>H]radioactivity incorporated into TG, revealing a significant elevation of [<sup>3</sup>H]TG in cells treated with the ORP10 siRNAs (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>). <fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Silencing of ORP10 enhances cholesterol and triglyceride biosynthesis in Huh7 cells. <bold>a</bold> Western blot analysis of ORP10 protein level in cells transfected for 48&#x000a0;h with nontargeting control (<italic>siNT</italic>) or ORP10-specific siRNAs (<italic>siORP10.1</italic>, <italic>siORP10.2</italic>) using INTERFERin. Anti-&#x003b2;-actin was used as a control for equal protein loading. The apparent molecular mass of the protein detected by the antibody (85&#x000a0;kDa) matches the ORP10 mass deduced from the cDNA sequence (83.97&#x000a0;kDa). <bold>b</bold> Incorporation of [<sup>3</sup>H]acetate into free cholesterol (<italic>FC</italic>), cholesteryl esters (<italic>CE</italic>), and triglycerides (<italic>TG</italic>) in cells treated with control or ORP10-specific siRNAs (<italic>N</italic>&#x02009;=&#x02009;4). <bold>c</bold> HMG-CoA reductase activity (expressed as [<sup>14</sup>C]HMG-CoA incorporation into mevalonic acid, DMP per milligrams membrane protein) in cells treated with control or ORP10-specific siRNAs (<italic>N</italic>&#x02009;=&#x02009;4). <bold>d</bold> Incorporation of [<sup>3</sup>H]oleic acid into triglycerides (TG) in cells treated with control or ORP10-specific siRNAs (<italic>N</italic>&#x02009;=&#x02009;4). The results represent mean &#x000b1; s.e.m. Statistical significance of the differences between values obtained for siNT and the ORP10-specific siRNAs was evaluated using Student&#x02019;s <italic>t</italic> test; *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01</p></caption><graphic position="anchor" xlink:href="109_2009_490_Fig3_HTML" id="MO3"/></fig></p><p>To investigate whether the elevation of [<sup>3</sup>H]cholesterol biosynthesis in Huh7 cells subjected to ORP10 silencing reflects a change in the activity of the rate-limiting enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, we determined in vitro the activity of this enzyme in membranes isolated from cells treated with ORP10-specific or control siRNAs. Incorporation of [<sup>14</sup>C]HMG-CoA into mevalonate was significantly (siORP10.1, 29%; siORP10.2, 21%) enhanced in cells subjected to ORP10 silencing as compared to those treated with the nontargeting control siRNA (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c</xref>). Furthermore, to test if the effect of <italic>OSBPL10</italic> silencing on TG biosynthesis occurs at the level of fatty acid biosynthesis or at the level of their activation or incorporation into TG, we assessed TG synthesis using [<sup>3</sup>H]oleic acid as the radioactive precursor. The results revealed enhancement in its incorporation into TG in cells subjected to ORP10 silencing, similar in its extent to the effect observed upon [<sup>3</sup>H]acetic acid labeling (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3d</xref>).</p><p>To investigate whether ORP10 might impact lipoprotein secretion by hepatic cells, we transferred Huh7 cells subjected to ORP10 silencing into serum-free medium and quantified, using specific ELISA assays, the secretion of apoA-I and apoB100. During a time course of up to 24&#x000a0;h, reduction of the cellular ORP10 induced a significant increase in the amount of apoB100 that accumulated in the growth medium, while no effect was detected on the accumulation of apoA-I (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a, b</xref>). At 12&#x000a0;h, the increase in apoB100 was 22% (siORP10.1) or 40% (siORP10.2) as compared to siNT-transfected cells; At 24&#x000a0;h, the corresponding numbers were 59% and 85%. Western analysis of the growth media was consistent with this finding (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4c</xref>; Electronic Supplementary Materials Fig.&#x000a0;<xref ref-type="supplementary-material" rid="MOESM3">2</xref>). <fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Silencing of ORP10 increases the accumulation of apoB100 in the growth medium. Accumulation of apoA-I (<bold>a</bold>) and apoB100 (<bold>b</bold>) into the growth medium of Huh7 cells treated with nontargeting (siNT) or ORP10-specific (siORP10.1, siORP10.2) siRNAs during a 24-h time course was quantified with specific sandwich ELISA assays. The data represents a mean &#x000b1; s.e.m. (<bold>a</bold><italic>N</italic>&#x02009;=&#x02009;3, <bold>b</bold><italic>N</italic>&#x02009;=&#x02009;5; *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, <italic>t</italic> test). <bold>c</bold> Analysis of apoB100 accumulation into growth medium at the indicated time points by Western blotting. An experiment representative of three independent analyses with similar results is shown</p></caption><graphic position="anchor" xlink:href="109_2009_490_Fig4_HTML" id="MO4"/></fig></p><p>To obtain clues of the mechanism by which ORP10 impacts cellular lipid metabolism, we analyzed by quantitative real-time RT-PCR the mRNAs for LXR&#x003b1;, LXR&#x003b2;, ABCA1, ABCG1<italic>,</italic> ABCG5, SREBP-1a, SREBP-1c, SREBP-2, HMG-CoA reductase, LDL-receptor, fatty acyl synthetase, stearoyl-CoA desaturase 1, Insig-1, and Insig-2. No significant change consistent with both ORP10-specific siRNAs was observed in these mRNAs upon silencing of <italic>OSBPL10</italic> (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). <fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>OSBPL10 silencing has no significant effect on the mRNAs for key factors involved in lipid metabolism. Huh7 cells were transfected for 48&#x000a0;h with control (siNT) or ORP10-specific siRNAs (siORP10.1, <italic>black bars</italic>; siORP10.2, <italic>gray bars</italic>), followed by total RNA isolation and quantitative RT-PCR analysis of mRNA levels. <italic>SREBP</italic> sterol regulatory element binding protein, <italic>LXR</italic> liver X receptor, <italic>HMGCoR</italic> 3-hydroxy-3-methylglutaryl coenzyme A reductase, <italic>LDLR</italic> low-density lipoprotein receptor, <italic>ABC</italic> ATP-binding cassette transporter, <italic>Insig</italic> insulin-induced gene, <italic>FAS</italic> fatty acyl synthase, <italic>SCD</italic> stearoyl coenzyme A desaturase-1. The data depict mRNA levels in ORP10 siRNA-treated cells relative to those in cells transfected with the scrambled control siRNA (siNT) and represents a mean &#x000b1; s.e.m. (<italic>N</italic>&#x02009;=&#x02009;4&#x02013;5)</p></caption><graphic position="anchor" xlink:href="109_2009_490_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec15"><title>ORP10 localizes on microtubules</title><p>To obtain clues of ORP10 function, we determined its intracellular localization. We transfected the human cell lines Huh7 (hepatoma), Caco-2 (colon carcinoma), and PANC-1 (pancreatic carcinoma) with EGFP- or Xpress epitope-tagged cDNA constructs and visualized the expressed proteins by confocal microscopy. The expressed ORP10 distributed between a cytosolic-appearing pool and fibril-like structures (Huh7, Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6a</xref>; Caco-2, Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6b</xref>; PANC-1, Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6c</xref>). Especially in cells expressing the protein at high levels, the fibrils often showed a cable-like, undulating morphology. The ORP10 fluorescence co-localized extensively with &#x003b2;-tubulin, identifying the filaments as microtubules. Localization of ORP10 on cable-like microtubule elements and the morphologic change induced by excess ORP10 were especially prominent in the human pancreatic carcinoma cell line PANC-1 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6d&#x02013;f</xref>; note the normal microtubule morphology in untransfected cells). However, ORP10 silencing using siRNA did not significantly affect the overall morphology of the microtubule cytoskeleton (data not shown). The identity of the ORP10 fibrils was further confirmed by treatment of transfected cells with the microtubule depolymerizing agent demecolcine, resulting in a dispersed, cytosolic distribution of ORP10 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6g</xref>). To investigate further the microtubule association of ORP10, PANC-1 cells expressing ORP10 were treated with vinblastine, which binds to &#x003b1;- and &#x003b2;-tubulin, prevents their polymerization, and allows formation of paracrystals consisting of both tubulins. ORP10 was found to decorate tubulin crystals in the vinblastine-treated cells, suggesting an intimate association with tubulin (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6h, i</xref>). No colocalization of ORP10 with vimentin (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6j</xref>) or cytokeratin (data not shown) intermediate filaments was observed. Identical results were obtained with the EGFP- and Xpress-epitope-tagged (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6k</xref>) constructs. To investigate whether manipulation of the cellular lipid status affects the localization of ORP10, we incubated Huh7 cells expressing EGFP-ORP10 for 48&#x000a0;h in lipoprotein-deficient medium. For some specimens, 50&#x02009;&#x003bc;M lovastatin was added for 24&#x000a0;h to potentiate the lipid/sterol depletion. For a comparison, cells were also incubated for 48&#x000a0;h with 100&#x02009;&#x003bc;g/ml of human LDL to increase the cellular lipid/sterol content or treated for 4&#x000a0;h with 5&#x02009;&#x003bc;M 25-hydroxycholesterol. Fluorescence microscopy analysis of EGFP-ORP10 revealed no significant effect of the lipid manipulations on the steady-state subcellular distribution of the protein (data not shown). <fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>ORP10 localizes on microtubules. Huh7, Caco-2, and PANC-1 cells transfected with EGFP-ORP10 were visualized by confocal fluorescence microscopy. <bold>a</bold> Transfected Huh7 cells. <bold>b</bold> A transfected Caco-2 cell. <bold>c</bold> A transfected PANC-1 cell. <bold>d</bold>&#x02013;<bold>f</bold> A transfected PANC-1 cell (<italic>arrow</italic>) surrounded by untransfected ones (<italic>arrowheads</italic>), costained with an antibody against &#x003b2;-tubulin. Note the aberrant bundled morphology of the EGFP-ORP10-positive microtubules in the transfected cell as compared to the normal microtubule cytoskeleton in the untransfected cells. <bold>g</bold> A transfected PANC-1 cell treated for 1&#x000a0;h with demecolcine (10&#x02009;&#x003bc;g/ml) to disrupt microtubules. <bold>h</bold>, <bold>i</bold> A transfected PANC-1 cell after 2&#x000a0;h treatment with vinblastine (10&#x02009;&#x003bc;g/ml), an agent that binds to &#x003b1;- and &#x003b2;-tubulin, prevents their polymerization and allows formation of tubulin paracrystals (indicated with <italic>arrows</italic>). <bold>j</bold> Channel merge image of a Huh7 cell expressing EGFP-ORP10 (<italic>green</italic>), stained for vimentin (<italic>red</italic>). <bold>k</bold> Huh7 cells transfected with ORP10/pcDNA4HisMaxC encoding ORP10 devoid of the EGFP fusion partner (staining with Xpress&#x02122; antibody). <italic>Bars</italic> 10&#x02009;&#x003bc;m. <bold>l</bold>. Huh7 cells transfected with EGFP-ORP10 were subjected to fluorescence recovery after photobleaching analysis using a live cell confocal microscopy setup. The recovery curve representing microtubule associated fluorescence in a bleached 6&#x02009;&#x000d7;&#x02009;6&#x02009;&#x003bc;m area as a function of time is displayed. The data represents a mean (<italic>N</italic>&#x02009;=&#x02009;8 cells) &#x000b1; s.e.m.; <italic>R</italic><sup>2</sup> of the fit&#x02009;=&#x02009;0.9993. Recovery half times for the two kinetic components are 4.5&#x02009;&#x000b1;&#x02009;0.94&#x000a0;s and 64.3&#x02009;&#x000b1;&#x02009;11.6&#x000a0;s</p></caption><graphic position="anchor" xlink:href="109_2009_490_Fig6_HTML" id="MO6"/></fig></p><p>To investigate the dynamic parameters of EGFP-ORP10 microtubule association, transfected Huh7 cells were subjected to fluorescence recovery after photobleaching analysis using a confocal microscope set up for live cell analysis. After photobleaching the microtubule-associated EGFP-ORP10, fluorescence recovered to approximately 70% of the starting value during the 6-min analysis period (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6l</xref>; <xref ref-type="supplementary-material" rid="MOESM1">Electronic Supplementary Materials: Time lapse video</xref>). The recovery followed a kinetics which curve-fitting suggested to arise from two components. The <italic>t</italic><sub>1/2</sub> for the fast component was 4.5&#x02009;&#x000b1;&#x02009;0.94&#x000a0;s, and that for the slow one was 64.3&#x02009;&#x000b1;&#x02009;11.6&#x000a0;s.</p></sec></sec><sec id="Sec16" sec-type="discussion"><title>Discussion</title><p>In the present study, we investigated a putative function of OSBP-related proteins in the regulation of serum lipids and lipoproteins in humans. Genotyping of <italic>OSBPL</italic> gene SNPs in a dyslipidemic family material was initially used to evaluate the contribution of <italic>OSBPL</italic> genes to extreme lipid levels predisposing to cardiovascular disease, high triglycerides, and low HDL. Although recent genome-wide association studies [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>] have initially identified common variants affecting lipid concentrations at the population level, data are also emerging for the impact of multiple rare variants influencing the extreme lipid levels [<xref ref-type="bibr" rid="CR24">24</xref>]. Here, we wanted to study such potential loci by testing the involvement of select <italic>OSBPL</italic> genes in carefully phenotyped Finnish families ascertained for dyslipidemias, low HDL, or FCHL. The FCHL study set revealed suggestive linkage of several SNPs in <italic>OSBPL10</italic> to the high TG trait, and analysis of the combined material strengthened the evidence. Importantly, association analysis using an independent study sample consisting of subjects with metabolic syndrome and matched healthy controls provided substantial proof for association of <italic>OSBPL10</italic> SNPs with the extreme end (&#x0003e;95th percentile) high-TG trait.</p><p>The genetic analyses suggest that variation within the chromosome 3p23 region containing <italic>OSBPL10</italic> may contribute to the high TG levels in Finnish dyslipidemic subjects. The present data do not allow us to firmly conclude that the underlying gene is <italic>OSBPL10</italic>, but they prompted us to investigate in more detail the function of the encoded protein, ORP10, in cultured cell models. The metabolic studies in cultured cells subjected to ORP10 silencing identify the protein as a novel regulator of hepatocellular lipid metabolism and apoB100 secretion, consistent with the notion that <italic>OSBPL10</italic> may be the gene underlying the genetic findings. The likelihood of this is further increased by the lack of other genes plausibly connected with lipid metabolism within the chromosome region (10&#x000a0;Mb interval).</p><p>Hepatoma cells subjected to ORP10 silencing displayed a significant increase in the incorporation of [<sup>3</sup>H]acetate into cholesterol and of [<sup>3</sup>H]acetate and [<sup>3</sup>H]oleic acid into TG, suggesting that the intrinsic function of ORP10 involves suppression of hepatocellular lipid biosyntheses. Consistent with this observation, the cells showed increased HMG-CoA reductase activity, demonstrating an effect already at an early stage of the pathway, on conversion of HMG-CoA to mevalonic acid. An independent, systematic esiRNA silencing screen of all ORP family members carried out in HeLa cells supported a role of ORP10 in the regulation of cholesterol biosynthesis (data not shown). Labeling with [<sup>3</sup>H]oleic acid suggested that the impact of ORP10 on TG biosynthesis occurs at the levels of fatty acid activation or acyl transfer to glycerol. Importantly, we also found that ORP10 silencing enhances the accumulation of apoB100 in the hepatoma cell growth medium. One can envision that ORP10 could affect the synthesis of TG and cholesterol as well as the assembly of TG-rich lipoproteins in the intestine and the liver, both tissues in which <italic>OSBPL10</italic> mRNA is expressed abundantly [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>ORP10 was found to distribute between a cytosolic localization and microtubules, a major apparatus determining the spatial distribution of organelles and forming tracks for intracellular transport events [<xref ref-type="bibr" rid="CR25">25</xref>]. FRAP analysis of live Huh7 cells with EGFP-ORP10 on microtubules revealed a recovery with two kinetic components. We find it likely that the fast component (<italic>t</italic><sub>1/2</sub>&#x02009;=&#x02009;4.5&#x000a0;s) reflects the diffusion of EGFP-ORP10 in the cytosolic compartment, while the slow component (<italic>t</italic><sub>1/2</sub>&#x02009;=&#x02009;64.3&#x000a0;s) could represent the actual microtubule association of the protein. The latter half-time is in the same range as the life-times determined for transport carriers moving along microtubules from the endoplasmic reticulum (ER) to the Golgi complex [<xref ref-type="bibr" rid="CR26">26</xref>] and from the <italic>trans</italic>-Golgi network to the plasma membrane [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. The data are thus consistent with the notion that ORP10 could be involved in microtubule-dependent membrane trafficking or organelle motility.</p><p>Microtubule-dependent membrane trafficking is intimately connected with the control of lipid metabolism. Importantly, the membrane compartments that play key roles in the cellular metabolism of cholesterol and triglycerides, the ER and cytoplasmic lipid droplets, are connected to microtubules, which determine the spatial organization of the ER [<xref ref-type="bibr" rid="CR29">29</xref>] and control the distribution and motility of lipid droplets [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Pertinent to serum lipoproteins, also the Golgi complex playing a central role in lipoprotein secretion is organized by microtubules [<xref ref-type="bibr" rid="CR32">32</xref>]. One can therefore envision that a protein associated with microtubules, such as ORP10, is in the position to modulate cellular lipid metabolism and lipoprotein secretion.</p></sec><sec sec-type="supplementary-material"><title>Electronic Supplementary Materials</title><supplementary-material id="N0x1cdc970N0x2d3ff48" content-type="local-data"><p>Below is the link to the electronic supplementary material. </p><media xlink:href="109_2009_490_MOESM1_ESM.avi" id="MOESM1" mimetype="video" mime-subtype="x-msvideo"><label>Supplemental Materials: Time Lapse Video</label><caption><p>(AVI 3486 kb)</p></caption></media><media xlink:href="109_2009_490_MOESM2_ESM.pdf" id="MOESM2" mimetype="application" mime-subtype="pdf"><label>Supplemental Tables&#x000a0;1 and 2</label><caption><p>(PDF 27 kb)</p></caption></media><media xlink:href="109_2009_490_MOESM3_ESM.pdf" id="MOESM3" mimetype="application" mime-subtype="pdf"><label>Supplemental Figs.&#x000a0;1 and 2</label><caption><p>(PDF 735 kb)</p></caption></media><media xlink:href="109_2009_490_MOESM4_ESM.pdf" id="MOESM4" mimetype="application" mime-subtype="pdf"><label>Supplemental Method Descriptions</label><caption><p>(PDF 44 kb)</p></caption></media></supplementary-material></sec></body><back><ack><p>We are grateful to Pipsa Kaipainen, Sari Nuutinen, Marja-Leena Piironen, Seija Puomilahti, and Pirjo Ranta for expert technical assistance. Dr. Markku Lehto is thanked for kindly providing the full-length ORP10 cDNA, Pekka Ellonen for help with the genotyping work, and Dr. Matti Jauhiainen for valuable comments on the manuscript. This study was supported by The Academy of Finland (grants 113013, 118720, and 121457 to V.M.O.), the European Union FP7 (LipidomicNet, agreement no. 202272), the Sigrid Juselius Foundation, the Finnish Foundation for Cardiovascular Research (M.-R.T., V.M.O.), the Magnus Ehrnrooth Foundation (V.M.O.), the Finnish Cultural Foundation (V.M.O.), and Helsinki University Central Hospital: A special governmental subsidy for health sciences research (M.-R.T., I.V.). Further support was provided by The Center of Excellence in Complex Disease Genetics (L.P., K.M., J.N.), The Research Program of Molecular Medicine, University of Helsinki, Biomedicum Foundation, and Biocentrum Helsinki Foundation (L.P., M.-R.T., K.M., J.N.).</p><p><bold>Disclosure statement</bold> Concerning this work, the authors have no conflicts of interest to declare.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fairn</surname><given-names>GD</given-names></name><name><surname>McMaster</surname><given-names>CR</given-names></name></person-group><article-title>Emerging roles of the oxysterol-binding protein family in metabolism, transport, and signaling</article-title><source>Cell Mol Life Sci</source><year>2007</year><volume>65</volume><fpage>228</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1007/s00018-007-7325-2</pub-id></citation><citation citation-type="display-unstructured">Fairn GD, McMaster CR (2007) Emerging roles of the oxysterol-binding protein family in metabolism, transport, and signaling. Cell Mol Life Sci 65:228&#x02013;236 <pub-id pub-id-type="pmid">17938859</pub-id></citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>D</given-names></name><name><surname>Olkkonen</surname><given-names>VM</given-names></name></person-group><article-title>Characteristics of oxysterol binding proteins</article-title><source>Int Rev Cytol</source><year>2008</year><volume>265</volume><fpage>253</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/S0074-7696(07)65007-4</pub-id></citation><citation citation-type="display-unstructured">Yan D, Olkkonen VM (2008) Characteristics of oxysterol binding proteins. Int Rev Cytol 265:253&#x02013;285 <pub-id pub-id-type="pmid">18275891</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jaworski</surname><given-names>CJ</given-names></name><name><surname>Moreira</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>R</given-names></name><name><surname>Rodriguez</surname><given-names>IR</given-names></name></person-group><article-title>A family of 12 human genes containing oxysterol-binding domains</article-title><source>Genomics</source><year>2001</year><volume>78</volume><fpage>185</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1006/geno.2001.6663</pub-id></citation><citation citation-type="display-unstructured">Jaworski CJ, Moreira E, Li A, Lee R, Rodriguez IR (2001) A family of 12 human genes containing oxysterol-binding domains. Genomics 78:185&#x02013;196 <pub-id pub-id-type="pmid">11735225</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lehto</surname><given-names>M</given-names></name><name><surname>Laitinen</surname><given-names>S</given-names></name><name><surname>Chinetti</surname><given-names>G</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Ehnholm</surname><given-names>C</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name><name><surname>Ikonen</surname><given-names>E</given-names></name><name><surname>Olkkonen</surname><given-names>VM</given-names></name></person-group><article-title>The OSBP-related protein family in humans</article-title><source>J Lipid Res</source><year>2001</year><volume>42</volume><fpage>1203</fpage><lpage>1213</lpage></citation><citation citation-type="display-unstructured">Lehto M, Laitinen S, Chinetti G, Johansson M, Ehnholm C, Staels B, Ikonen E, Olkkonen VM (2001) The OSBP-related protein family in humans. J Lipid Res 42:1203&#x02013;1213 <pub-id pub-id-type="pmid">11483621</pub-id></citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>RJ</given-names></name><name><surname>Ridgway</surname><given-names>ND</given-names></name></person-group><article-title>Oxysterol-binding protein and vesicle-associated membrane protein-associated protein are required for sterol-dependent activation of the ceramide transport protein</article-title><source>Mol Biol Cell</source><year>2006</year><volume>17</volume><fpage>2604</fpage><lpage>2616</lpage><pub-id pub-id-type="doi">10.1091/mbc.E06-01-0060</pub-id></citation><citation citation-type="display-unstructured">Perry RJ, Ridgway ND (2006) Oxysterol-binding protein and vesicle-associated membrane protein-associated protein are required for sterol-dependent activation of the ceramide transport protein. Mol Biol Cell 17:2604&#x02013;2616 <pub-id pub-id-type="pmid">16571669</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>PY</given-names></name><name><surname>Weng</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>RG</given-names></name></person-group><article-title>OSBP is a cholesterol-regulated scaffolding protein in control of ERK 1/2 activation</article-title><source>Science</source><year>2005</year><volume>307</volume><fpage>1472</fpage><lpage>1476</lpage><pub-id pub-id-type="doi">10.1126/science.1107710</pub-id></citation><citation citation-type="display-unstructured">Wang PY, Weng J, Anderson RG (2005) OSBP is a cholesterol-regulated scaffolding protein in control of ERK 1/2 activation. Science 307:1472&#x02013;1476 <pub-id pub-id-type="pmid">15746430</pub-id></citation></ref><ref id="CR7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>D</given-names></name><name><surname>Lehto</surname><given-names>M</given-names></name><name><surname>Rasilainen</surname><given-names>L</given-names></name><name><surname>Metso</surname><given-names>J</given-names></name><name><surname>Ehnholm</surname><given-names>C</given-names></name><name><surname>Yl&#x000e4;-Herttuala</surname><given-names>S</given-names></name><name><surname>Jauhiainen</surname><given-names>M</given-names></name><name><surname>Olkkonen</surname><given-names>VM</given-names></name></person-group><article-title>Oxysterol binding protein induces upregulation of SREBP-1c and enhances hepatic lipogenesis</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2007</year><volume>27</volume><fpage>1108</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.106.138545</pub-id></citation><citation citation-type="display-unstructured">Yan D, Lehto M, Rasilainen L, Metso J, Ehnholm C, Yl&#x000e4;-Herttuala S, Jauhiainen M, Olkkonen VM (2007) Oxysterol binding protein induces upregulation of SREBP-1c and enhances hepatic lipogenesis. Arterioscler Thromb Vasc Biol 27:1108&#x02013;1114 <pub-id pub-id-type="pmid">17303778</pub-id></citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>D</given-names></name><name><surname>Jauhiainen</surname><given-names>M</given-names></name><name><surname>Hildebrand</surname><given-names>RB</given-names></name><name><surname>Willems van Dijk</surname><given-names>K</given-names></name><name><surname>Berkel</surname><given-names>TJ</given-names></name><name><surname>Ehnholm</surname><given-names>C</given-names></name><name><surname>Eck</surname><given-names>M</given-names></name><name><surname>Olkkonen</surname><given-names>VM</given-names></name></person-group><article-title>Expression of human OSBP-related protein 1L in macrophages enhances atherosclerotic lesion development in LDL receptor-deficient mice</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2007</year><volume>27</volume><fpage>1618</fpage><lpage>1624</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.107.144121</pub-id></citation><citation citation-type="display-unstructured">Yan D, Jauhiainen M, Hildebrand RB, Willems van Dijk K, Van Berkel TJ, Ehnholm C, Van Eck M, Olkkonen VM (2007) Expression of human OSBP-related protein 1L in macrophages enhances atherosclerotic lesion development in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 27:1618&#x02013;1624 <pub-id pub-id-type="pmid">17478758</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>D</given-names></name><name><surname>M&#x000e4;yr&#x000e4;np&#x000e4;&#x000e4;</surname><given-names>MI</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name><name><surname>Perttil&#x000e4;</surname><given-names>J</given-names></name><name><surname>Lehto</surname><given-names>M</given-names></name><name><surname>Jauhiainen</surname><given-names>M</given-names></name><name><surname>Kovanen</surname><given-names>PT</given-names></name><name><surname>Ehnholm</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>AJ</given-names></name><name><surname>Olkkonen</surname><given-names>VM</given-names></name></person-group><article-title>OSBP-related protein 8 (ORP8) suppresses ABCA1 expression and cholesterol efflux from macrophages</article-title><source>J Biol Chem</source><year>2007</year><volume>283</volume><fpage>332</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1074/jbc.M705313200</pub-id></citation><citation citation-type="display-unstructured">Yan D, M&#x000e4;yr&#x000e4;np&#x000e4;&#x000e4; MI, Wong J, Perttil&#x000e4; J, Lehto M, Jauhiainen M, Kovanen PT, Ehnholm C, Brown AJ, Olkkonen VM (2007) OSBP-related protein 8 (ORP8) suppresses ABCA1 expression and cholesterol efflux from macrophages. J Biol Chem 283:332&#x02013;340 <pub-id pub-id-type="pmid">17991739</pub-id></citation></ref><ref id="CR10"><label>10.</label><citation citation-type="other">Hynynen R, Suchanek M, Spandl J, Back N, Thiele C, Olkkonen VM (2009) OSBP-related protein 2 (ORP2) is a sterol receptor on lipid droplets that regulates the metabolism of neutral lipids. J Lipid Res 50:1305&#x02013;1315</citation></ref><ref id="CR11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>M</given-names></name><name><surname>Ridgway</surname><given-names>ND</given-names></name></person-group><article-title>Oxysterol binding protein-related Protein 9 (ORP9) is a cholesterol transfer protein that regulates Golgi structure and function</article-title><source>Mol Biol Cell</source><year>2009</year><volume>20</volume><fpage>1388</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1091/mbc.E08-09-0905</pub-id></citation><citation citation-type="display-unstructured">Ngo M, Ridgway ND (2009) Oxysterol binding protein-related Protein 9 (ORP9) is a cholesterol transfer protein that regulates Golgi structure and function. Mol Biol Cell 20:1388&#x02013;1399 <pub-id pub-id-type="pmid">19129476</pub-id></citation></ref><ref id="CR12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>JeBailey</surname><given-names>L</given-names></name><name><surname>Ridgway</surname><given-names>ND</given-names></name></person-group><article-title>Oxysterol-binding-protein (OSBP)-related protein 4 binds 25-hydroxycholesterol and interacts with vimentin intermediate filaments</article-title><source>Biochem J</source><year>2002</year><volume>361</volume><fpage>461</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1042/0264-6021:3610461</pub-id></citation><citation citation-type="display-unstructured">Wang C, JeBailey L, Ridgway ND (2002) Oxysterol-binding-protein (OSBP)-related protein 4 binds 25-hydroxycholesterol and interacts with vimentin intermediate filaments. Biochem J 361:461&#x02013;472 <pub-id pub-id-type="pmid">11802775</pub-id></citation></ref><ref id="CR13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Genest</surname><given-names>JJ</given-names><suffix>Jr</suffix></name><name><surname>Martin-Munley</surname><given-names>SS</given-names></name><name><surname>McNamara</surname><given-names>JR</given-names></name><name><surname>Ordovas</surname><given-names>JM</given-names></name><name><surname>Jenner</surname><given-names>J</given-names></name><name><surname>Myers</surname><given-names>RH</given-names></name><name><surname>Silberman</surname><given-names>SR</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>Salem</surname><given-names>DN</given-names></name><name><surname>Schaefer</surname><given-names>EJ</given-names></name></person-group><article-title>Familial lipoprotein disorders in patients with premature coronary artery disease</article-title><source>Circulation</source><year>1992</year><volume>85</volume><fpage>2025</fpage><lpage>2033</lpage></citation><citation citation-type="display-unstructured">Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PW, Salem DN, Schaefer EJ (1992) Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 85:2025&#x02013;2033 <pub-id pub-id-type="pmid">1534286</pub-id></citation></ref><ref id="CR14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Schrott</surname><given-names>HG</given-names></name><name><surname>Hazzard</surname><given-names>WR</given-names></name><name><surname>Bierman</surname><given-names>EL</given-names></name><name><surname>Motulsky</surname><given-names>AG</given-names></name></person-group><article-title>Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia</article-title><source>J Clin Invest</source><year>1973</year><volume>52</volume><fpage>1544</fpage><lpage>1568</lpage><pub-id pub-id-type="doi">10.1172/JCI107332</pub-id></citation><citation citation-type="display-unstructured">Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG (1973) Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52:1544&#x02013;1568 <pub-id pub-id-type="pmid">4718953</pub-id></citation></ref><ref id="CR15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nikkil&#x000e4;</surname><given-names>EA</given-names></name><name><surname>Aro</surname><given-names>A</given-names></name></person-group><article-title>Family study of serum lipids and lipoproteins in coronary heart-disease</article-title><source>Lancet</source><year>1973</year><volume>1</volume><fpage>954</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(73)91598-5</pub-id></citation><citation citation-type="display-unstructured">Nikkil&#x000e4; EA, Aro A (1973) Family study of serum lipids and lipoproteins in coronary heart-disease. Lancet 1:954&#x02013;959 <pub-id pub-id-type="pmid">4121585</pub-id></citation></ref><ref id="CR16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>O</given-names></name><name><surname>Stein</surname><given-names>Y</given-names></name></person-group><article-title>Atheroprotective mechanisms of HDL</article-title><source>Atherosclerosis</source><year>1999</year><volume>144</volume><fpage>285</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/S0021-9150(99)00065-9</pub-id></citation><citation citation-type="display-unstructured">Stein O, Stein Y (1999) Atheroprotective mechanisms of HDL. Atherosclerosis 144:285&#x02013;301 <pub-id pub-id-type="pmid">10407490</pub-id></citation></ref><ref id="CR17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pajukanta</surname><given-names>P</given-names></name><name><surname>Nuotio</surname><given-names>I</given-names></name><name><surname>Terwilliger</surname><given-names>JD</given-names></name><name><surname>Porkka</surname><given-names>KV</given-names></name><name><surname>Ylitalo</surname><given-names>K</given-names></name><name><surname>Pihlajam&#x000e4;ki</surname><given-names>J</given-names></name><name><surname>Suomalainen</surname><given-names>AJ</given-names></name><name><surname>Syvanen</surname><given-names>AC</given-names></name><name><surname>Lehtim&#x000e4;ki</surname><given-names>T</given-names></name><name><surname>Viikari</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Linkage of familial combined hyperlipidaemia to chromosome 1q21&#x02013;q23</article-title><source>Nat Genet</source><year>1998</year><volume>18</volume><fpage>369</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1038/ng0498-369</pub-id></citation><citation citation-type="display-unstructured">Pajukanta P, Nuotio I, Terwilliger JD, Porkka KV, Ylitalo K, Pihlajam&#x000e4;ki J, Suomalainen AJ, Syvanen AC, Lehtim&#x000e4;ki T, Viikari JS et al (1998) Linkage of familial combined hyperlipidaemia to chromosome 1q21&#x02013;q23. Nat Genet 18:369&#x02013;373 <pub-id pub-id-type="pmid">9537421</pub-id></citation></ref><ref id="CR18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soro</surname><given-names>A</given-names></name><name><surname>Pajukanta</surname><given-names>P</given-names></name><name><surname>Lilja</surname><given-names>HE</given-names></name><name><surname>Ylitalo</surname><given-names>K</given-names></name><name><surname>Hiekkalinna</surname><given-names>T</given-names></name><name><surname>Perola</surname><given-names>M</given-names></name><name><surname>Cantor</surname><given-names>RM</given-names></name><name><surname>Viikari</surname><given-names>JS</given-names></name><name><surname>Taskinen</surname><given-names>MR</given-names></name><name><surname>Peltonen</surname><given-names>L</given-names></name></person-group><article-title>Genome scans provide evidence for low-HDL-C loci on chromosomes 8q23, 16q24.1&#x02013;24.2, and 20q13.11 in Finnish families</article-title><source>Am J Hum Genet</source><year>2002</year><volume>70</volume><fpage>1333</fpage><lpage>1340</lpage><pub-id pub-id-type="doi">10.1086/339988</pub-id></citation><citation citation-type="display-unstructured">Soro A, Pajukanta P, Lilja HE, Ylitalo K, Hiekkalinna T, Perola M, Cantor RM, Viikari JS, Taskinen MR, Peltonen L (2002) Genome scans provide evidence for low-HDL-C loci on chromosomes 8q23, 16q24.1&#x02013;24.2, and 20q13.11 in Finnish families. Am J Hum Genet 70:1333&#x02013;1340 <pub-id pub-id-type="pmid">11891617</pub-id></citation></ref><ref id="CR19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haperen</surname><given-names>R</given-names></name><name><surname>Tol</surname><given-names>A</given-names></name><name><surname>Vermeulen</surname><given-names>P</given-names></name><name><surname>Jauhiainen</surname><given-names>M</given-names></name><name><surname>Gent</surname><given-names>T</given-names></name><name><surname>Berg</surname><given-names>P</given-names></name><name><surname>Ehnholm</surname><given-names>S</given-names></name><name><surname>Grosveld</surname><given-names>F</given-names></name><name><surname>Kamp</surname><given-names>A</given-names></name><name><surname>Crom</surname><given-names>R</given-names></name></person-group><article-title>Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2000</year><volume>20</volume><fpage>1082</fpage><lpage>1088</lpage></citation><citation citation-type="display-unstructured">van Haperen R, van Tol A, Vermeulen P, Jauhiainen M, van Gent T, van den Berg P, Ehnholm S, Grosveld F, van der Kamp A, de Crom R (2000) Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 20:1082&#x02013;1088 <pub-id pub-id-type="pmid">10764677</pub-id></citation></ref><ref id="CR20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Olkkonen</surname><given-names>VM</given-names></name></person-group><article-title>Assays for interaction between Rab7 and oxysterol binding protein related protein 1L (ORP1L)</article-title><source>Methods Enzymol</source><year>2005</year><volume>403</volume><fpage>743</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1016/S0076-6879(05)03065-X</pub-id></citation><citation citation-type="display-unstructured">Johansson M, Olkkonen VM (2005) Assays for interaction between Rab7 and oxysterol binding protein related protein 1L (ORP1L). Methods Enzymol 403:743&#x02013;758 <pub-id pub-id-type="pmid">16473636</pub-id></citation></ref><ref id="CR21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kathiresan</surname><given-names>S</given-names></name><name><surname>Melander</surname><given-names>O</given-names></name><name><surname>Guiducci</surname><given-names>C</given-names></name><name><surname>Surti</surname><given-names>A</given-names></name><name><surname>Burtt</surname><given-names>NP</given-names></name><name><surname>Rieder</surname><given-names>MJ</given-names></name><name><surname>Cooper</surname><given-names>GM</given-names></name><name><surname>Roos</surname><given-names>C</given-names></name><name><surname>Voight</surname><given-names>BF</given-names></name><name><surname>Havulinna</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>189</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/ng.75</pub-id></citation><citation citation-type="display-unstructured">Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, Cooper GM, Roos C, Voight BF, Havulinna AS et al (2008) Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 40:189&#x02013;197 <pub-id pub-id-type="pmid">18193044</pub-id></citation></ref><ref id="CR22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kathiresan</surname><given-names>S</given-names></name><name><surname>Willer</surname><given-names>CJ</given-names></name><name><surname>Peloso</surname><given-names>GM</given-names></name><name><surname>Demissie</surname><given-names>S</given-names></name><name><surname>Musunuru</surname><given-names>K</given-names></name><name><surname>Schadt</surname><given-names>EE</given-names></name><name><surname>Kaplan</surname><given-names>L</given-names></name><name><surname>Bennett</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><etal/></person-group><article-title>Common variants at 30 loci contribute to polygenic dyslipidemia</article-title><source>Nat Genet</source><year>2009</year><volume>41</volume><fpage>56</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/ng.291</pub-id></citation><citation citation-type="display-unstructured">Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, Kaplan L, Bennett D, Li Y, Tanaka T et al (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 41:56&#x02013;65 <pub-id pub-id-type="pmid">19060906</pub-id></citation></ref><ref id="CR23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willer</surname><given-names>CJ</given-names></name><name><surname>Sanna</surname><given-names>S</given-names></name><name><surname>Jackson</surname><given-names>AU</given-names></name><name><surname>Scuteri</surname><given-names>A</given-names></name><name><surname>Bonnycastle</surname><given-names>LL</given-names></name><name><surname>Clarke</surname><given-names>R</given-names></name><name><surname>Heath</surname><given-names>SC</given-names></name><name><surname>Timpson</surname><given-names>NJ</given-names></name><name><surname>Najjar</surname><given-names>SS</given-names></name><name><surname>Stringham</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Newly identified loci that influence lipid concentrations and risk of coronary artery disease</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1038/ng.76</pub-id></citation><citation citation-type="display-unstructured">Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM et al (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40:161&#x02013;169 <pub-id pub-id-type="pmid">18193043</pub-id></citation></ref><ref id="CR24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JC</given-names></name><name><surname>Pertsemlidis</surname><given-names>A</given-names></name><name><surname>Fahmi</surname><given-names>S</given-names></name><name><surname>Esmail</surname><given-names>S</given-names></name><name><surname>Vega</surname><given-names>GL</given-names></name><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Hobbs</surname><given-names>HH</given-names></name></person-group><article-title>Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><fpage>1810</fpage><lpage>1815</lpage><pub-id pub-id-type="doi">10.1073/pnas.0508483103</pub-id></citation><citation citation-type="display-unstructured">Cohen JC, Pertsemlidis A, Fahmi S, Esmail S, Vega GL, Grundy SM, Hobbs HH (2006) Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci U S A 103:1810&#x02013;1815 <pub-id pub-id-type="pmid">16449388</pub-id></citation></ref><ref id="CR25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Welte</surname><given-names>MA</given-names></name></person-group><article-title>Bidirectional transport along microtubules</article-title><source>Curr Biol</source><year>2004</year><volume>14</volume><fpage>R525</fpage><lpage>R537</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2004.06.045</pub-id></citation><citation citation-type="display-unstructured">Welte MA (2004) Bidirectional transport along microtubules. Curr Biol 14:R525&#x02013;R537 <pub-id pub-id-type="pmid">15242636</pub-id></citation></ref><ref id="CR26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Presley</surname><given-names>JF</given-names></name><name><surname>Cole</surname><given-names>NB</given-names></name><name><surname>Schroer</surname><given-names>TA</given-names></name><name><surname>Hirschberg</surname><given-names>K</given-names></name><name><surname>Zaal</surname><given-names>KJ</given-names></name><name><surname>Lippincott-Schwartz</surname><given-names>J</given-names></name></person-group><article-title>ER-to-Golgi transport visualized in living cells</article-title><source>Nature</source><year>1997</year><volume>389</volume><fpage>81</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/38891</pub-id></citation><citation citation-type="display-unstructured">Presley JF, Cole NB, Schroer TA, Hirschberg K, Zaal KJ, Lippincott-Schwartz J (1997) ER-to-Golgi transport visualized in living cells. Nature 389:81&#x02013;85. doi:10.1038/38001 <pub-id pub-id-type="pmid">9288971</pub-id></citation></ref><ref id="CR27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirschberg</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>CM</given-names></name><name><surname>Ellenberg</surname><given-names>J</given-names></name><name><surname>Presley</surname><given-names>JF</given-names></name><name><surname>Siggia</surname><given-names>ED</given-names></name><name><surname>Phair</surname><given-names>RD</given-names></name><name><surname>Lippincott-Schwartz</surname><given-names>J</given-names></name></person-group><article-title>Kinetic analysis of secretory protein traffic and characterization of golgi to plasma membrane transport intermediates in living cells</article-title><source>J Cell Biol</source><year>1998</year><volume>143</volume><fpage>1485</fpage><lpage>1503</lpage><pub-id pub-id-type="doi">10.1083/jcb.143.6.1485</pub-id></citation><citation citation-type="display-unstructured">Hirschberg K, Miller CM, Ellenberg J, Presley JF, Siggia ED, Phair RD, Lippincott-Schwartz J (1998) Kinetic analysis of secretory protein traffic and characterization of golgi to plasma membrane transport intermediates in living cells. J Cell Biol 143:1485&#x02013;1503 <pub-id pub-id-type="pmid">9852146</pub-id></citation></ref><ref id="CR28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toomre</surname><given-names>D</given-names></name><name><surname>Keller</surname><given-names>P</given-names></name><name><surname>White</surname><given-names>J</given-names></name><name><surname>Olivo</surname><given-names>JC</given-names></name><name><surname>Simons</surname><given-names>K</given-names></name></person-group><article-title>Dual-color visualization of trans-Golgi network to plasma membrane traffic along microtubules in living cells</article-title><source>J Cell Sci</source><year>1999</year><volume>112</volume><issue>Pt 1</issue><fpage>21</fpage><lpage>33</lpage></citation><citation citation-type="display-unstructured">Toomre D, Keller P, White J, Olivo JC, Simons K (1999) Dual-color visualization of trans-Golgi network to plasma membrane traffic along microtubules in living cells. J Cell Sci 112(Pt 1):21&#x02013;33 <pub-id pub-id-type="pmid">9841901</pub-id></citation></ref><ref id="CR29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vedrenne</surname><given-names>C</given-names></name><name><surname>Hauri</surname><given-names>HP</given-names></name></person-group><article-title>Morphogenesis of the endoplasmic reticulum: beyond active membrane expansion</article-title><source>Traffic</source><year>2006</year><volume>7</volume><fpage>639</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0854.2006.00419.x</pub-id></citation><citation citation-type="display-unstructured">Vedrenne C, Hauri HP (2006) Morphogenesis of the endoplasmic reticulum: beyond active membrane expansion. Traffic 7:639&#x02013;646 <pub-id pub-id-type="pmid">16683914</pub-id></citation></ref><ref id="CR30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>RS</given-names></name></person-group><article-title>Microtubule motors: LSD2 trips the toggle</article-title><source>Curr Biol</source><year>2005</year><volume>15</volume><fpage>R651</fpage><lpage>R653</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2005.08.027</pub-id></citation><citation citation-type="display-unstructured">Cohen RS (2005) Microtubule motors: LSD2 trips the toggle. Curr Biol 15:R651&#x02013;R653 <pub-id pub-id-type="pmid">16139192</pub-id></citation></ref><ref id="CR31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Welte</surname><given-names>MA</given-names></name><name><surname>Cermelli</surname><given-names>S</given-names></name><name><surname>Griner</surname><given-names>J</given-names></name><name><surname>Viera</surname><given-names>A</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Gindhart</surname><given-names>JG</given-names></name><name><surname>Gross</surname><given-names>SP</given-names></name></person-group><article-title>Regulation of lipid-droplet transport by the perilipin homolog LSD2</article-title><source>Curr Biol</source><year>2005</year><volume>15</volume><fpage>1266</fpage><lpage>1275</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2005.06.062</pub-id></citation><citation citation-type="display-unstructured">Welte MA, Cermelli S, Griner J, Viera A, Guo Y, Kim DH, Gindhart JG, Gross SP (2005) Regulation of lipid-droplet transport by the perilipin homolog LSD2. Curr Biol 15:1266&#x02013;1275 <pub-id pub-id-type="pmid">16051169</pub-id></citation></ref><ref id="CR32"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rios</surname><given-names>RM</given-names></name><name><surname>Bornens</surname><given-names>M</given-names></name></person-group><article-title>The Golgi apparatus at the cell centre</article-title><source>Curr Opin Cell Biol</source><year>2003</year><volume>15</volume><fpage>60</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/S0955-0674(02)00013-3</pub-id></citation><citation citation-type="display-unstructured">Rios RM, Bornens M (2003) The Golgi apparatus at the cell centre. Curr Opin Cell Biol 15:60&#x02013;66 <pub-id pub-id-type="pmid">12517705</pub-id></citation></ref></ref-list><fn-group><fn><p>Julia Perttil&#x000e4; and Krista Merikanto contributed equally to this work.</p></fn><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1007/s00109-009-0490-z) contains supplementary material, which is available to authorized users.</p></fn></fn-group></back></article> 